Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: https://www.allarity.com
4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)